Dear Flowers, I have several questions about MRD in AML patients. It will be highly appreciated if any one could help in these questions or had any experience in this field. as you know in AML, sometimes we can get more than one blast subset in which some markers will appear positive in one blast subset and negative in the other blast subset , so what is the best way of gating on the blast population? Is it by gating on the whole blast population or taking every blast subset as individual gate. The other thing is we always use the progenitor markers as CD34 and CD117 as indication of blast population by back gating to identify the blast population , however, there are some cases of AML where we can find CD34 negative or CD117 negative so what is the best way to identify the blast population in these cases. Another question is: in cases of M4 or M5 , the blast population always merged into the monocyte population and that is expected!! in these cases, however, we always expect to find some of the markers positive for monocyte like CD64, CD65 or CD11b , so here what is the best way to identify the leukemia-associated phenotpes (LAP), will we still look at the co-expression of the progenitors and these markers, what if in this case of negative CD34 or negative CD117?? The last question is : in the follow up samples where you expect to find very few blasts, what is the best way of gating, I think it is very important to identify the right blast population in this case which was in the same place at diagnosis. Any help in these questions will greatly appreciated Thank you very much in advance Kind regards, Mrs. Adhra Al-Mawali PhD student- University of Adelaide Institute of Medical and Veterinary Science (IMVS) Division of Immunology and Haematology South Australia Frome Road, Adelaide SA 5000 Tel (61) 8 8222 3491 Fax (61) 8 8222 3485Received on Fri Nov 18 14:38:00 2005
This archive was generated by hypermail 2.1.8 : Sat Jan 14 2006 - 22:03:59 EST
